04.

News

Find out the latest news about NextCell
2020-12-23

NextCell Pharma’s rights issue was oversubscribed

NextCell Pharma AB ("NextCell" or the ”Company”) announces today the outcome in the Company’s new issue of shares with preferential rights for existing shareholders of approximately SEK 150 million (the “Rights Issue”). The Rights Issue was oversubscribed. Thus, no guarantees have been utilized. ...
Read more
2020-12-16

NextCell Pharma publishes prospectus supplement

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SWITZERLAND, SINGAPORE OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFU...
Read more
2020-12-15

ProTrans Observation Study for long term efficacy in diabetes

NextCell Pharma AB (“NextCell” or “the Company”) today announces that an observational study, ProTrans-OBS, has been approved by the Swedish Ethical Review Board for long-term follow-up of patients previously participating in the ProTrans-2 clinical trial. The study is conducted by professor Per-...
Read more
2020-12-10

ProTrans demonstrates effect at 2 years after repeated treatments

NextCell Pharma AB ("NextCell") today announces that the ProTrans-Repeat trial met its primary safety endpoint. There were no severe adverse events recorded during the 12-month follow-up period after a second dose of ProTrans™ (ProTrans). Furthermore, a strong tendency of sustained efficacy was o...
Read more
2020-12-03
NextCell Pharma publishes prospectus relating to the rights issue
The Board of Directors of NextCell Pharma AB ("NextCell" or the “Company”) has prepared a prospectus (the “Prospectus”) relating to the new issue of shares with preferential rights for existing shareholders of approximately SEK 150 million (the Rights Issue”), which was resolved by the Board of D...
Read more
2020-11-20
The Board of Directors of NextCell Pharma intends on resolving on a fully guaranteed preferential rights issue of approximately SEK 150 million
The Board of Directors of NextCell Pharma AB (“NextCell” or the “Company”) today announces its intention to resolve on a fully guaranteed rights issue of up to approximately SEK 150 million with preferential rights for the Company’s existing shareholders (the “Rights Issue”). The Board of Directo...
Read more
2020-11-16
NextCell supports ProTrans study for children and adolescents
NextCell Pharma AB (“NextCell”) has entered into an agreement with Professor Per-Ola Carlsson, at Uppsala University Hospital and Uppsala University, with the aim of contributing the stem cell product ProTrans™ (ProTrans) for the treatment of children and adolescents with type 1 diabetes, within ...
Read more
2020-11-09
NextCell has formally kicked-off its Eurostars funded project ‘ Bioscale ’
NextCell Pharma AB (“NextCell” or the “Company”) announces today that it, in cooperation with the consortium members: MyCellHub, SEFA and Scinus Cell Expansion, now officially has kicked-off the earlier announced Eurostars project. The Eurostars project Bioscale will focus on using a novel cell e...
Read more
2020-10-30
NextCell publishes its Year-End Report
NextCell Pharma AB (publ) (NXTCL) publishes its Year-End Report for the period September 1, 2019 - August 31, 2020 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report NextCells share is traded on Nasdaq First North Growth Market under th...
Read more
2020-10-29
Study design and plan for the recently approved COVID-19 study with ProTrans
NextCell Pharma AB (“NextCell” or “the Company”) announced last week that a clinical trial with the stem cell therapy product ProTrans for the treatment of patients with COVID-19 has been approved. A total of nine patients will be treated within this phase 1b study, called "ProTrans 19+". The com...
Read more
2020-10-21
ProTrans stem cells approved for clinical trials in COVID-19 patients
NextCell Pharma AB ("NextCell") today announces that the application for clinical trial of COVID-19 patients with the drug candidate ProTrans has been approved by both the Ethics Committy and the Swedish Medical Product Agency. The study will be conducted at the University Hospital in Örebro in c...
Read more
2020-10-14
NextCell presents at “Investerarjakten”
NextCell Pharma AB (“NextCell”) will today at 15:00 present at Investerarjakten. Viewers have the possibility to ask questions directly to CEO Mathias Svahn. The event is broadcast live on Studio Direct's youtube channel, the facebook group Aktier and on Investerarbrevet.se between 13:00-17:00. ...
Read more

News

16/12/2020
Interview with the CEO in Biostock
NextCell Pharma's CEO has a clear vision
Read more
10/12/2020
Article in Biostock
A right issue will enable a Phase III study
Read more
15/6/2020
Interview with the CEO in Biostock
NextCell Pharma wants to rethink the treatment paradigm for diabetes.
Read more
10/6/2020
Article about NextCell Pharma in Biostock
NextCell Pharma will pass several milestones via share issue
Read more
6/5/2020
Interview with NextCell Pharma's CEO Mathias Svahn
Our fully recruited Phase 2-study is almost finished and we see no risk for delays despite the current pandemic. The results are as expected for Q3.
Read more
6/4/2020
The stem cell treatment that could stop diabetes
Diabetes is increasing among children and young people. Today the disease is incurable, but the stem cell company NextCell Pharma believes that diabetes and several other diseases could be treated with stem cells.
Read more

Company Presentations

Ladda ner

Expert Event

Independent diabetes and cell therapy experts comment on data published.
Ladda ner

News announcement

NextCell Pharma - ProTrans shows significant effect in diabetes
Ladda ner

Aktiespararnas aktiedag, 2020-05-04

CEO Mathias Svahn presents the company (in Swedish)
Ladda ner

Elevator Pitch

A short video where CEO Mathias Svahn introduces the company

Company Analyses

6/17/2019
Analyst Group
Bull & Bear-Analysis
New capital enables completion of Phase I/II
Read more
6/13/2019
SvD Näringsliv
Nextcell Pharma: A rare investment opportunity
The stem cell company NextCell is currently issuing new shares to finance the ongoing development of their drug candidate ProTrans. (Article in Swedish)
Read more
8/10/2018
Analyst Group
Bull & Bear-Analysis
Unique stem cell company with potential within several diseases
Read more